Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent live attenuated influenza vaccine
- Development stage
- Approved
- Lead developer
- MedImmune
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
A quadrivalent live attenuated influenza vaccine (LAIV4) is a needle-free, intranasal vaccine designed to protect against four different influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). Unlike inactivated vaccines, LAIV contains weakened (attenuated) viruses that are cold-adapted and temperature-sensitive, allowing them to replicate in the cooler environment of the nasopharynx but not in the warmer lower respiratory tract. This modality induces both mucosal and systemic immunity, mimicking natural infection without causing disease. The most prominent commercial version is FluMist (developed by MedImmune/AstraZeneca). It is typically indicated for healthy individuals aged 2 to 49 years.
- Brand names
- FluMistFluenz TetraGanwu
- Other names
- LAIV4LAIV-4LAIV 4Q/LAIVNasal Spray Lyophilized Live Attenuated Influenza Vaccineinfluenza vaccine (live attenuated, nasal)
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent live attenuated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent live attenuated influenza vaccine.